bio2018special programs

SPARK Network Showcase of Translational Research Presentations

1:00 PM–5:00 PM Jun 3, 2019 (US - Eastern)

110AB, Level 100


Hosted by the SPARK at Stanford Program.

The BIO SPARK Showcase aims to provide an excellent opportunity for academic researchers in the SPARK network to showcase drug development and medical technology programs that are ready for partnering or venture funding. Academics ready to pursue partnering will present their programs and also have one-on-one discussions with interested parties.

1:00 PM: Welcome from SPARK Translational Research Program, Stanford Medicine

1:05 PM: Stanford University- SPARK at Stanford, Novel Treatment for Kidney Cancer, Arvin Gouw / Dean Felsher

1:20 PM: SPARK Norway, A novel vaccine platform against influenza, Gunnveig Grødeland

1:40 PM: Stanford University- Exogene Therapeutics, Exosome platform for tissue-specific drug delivery of mRNA or other therapeutic cargo, Michael Imperiale

2:00 PM: SPARK Taiwan, First-in-Class therapeutics for migraine and schizophrenia, Dr. Chiou

2:20 PM: Stanford University -- Recombia, MAGESTIC - A High Efficiency, Massively Parallel Production of Genetically Engineered Clones for Functional Genomics and Synthetic Biology, Justin Smith

2:40 PM: SPARK Finland, Novel treatment modality for Limbal Epithelial Stem Cell Deficiency, Anni Mörö

3:00 PM: Stanford University- SPARK at Stanford, Transient telomere extension to treat liver failure in dyskeratosis congenita patients, John Ramunas

3:20 PM: SPARK Taiwan, New Drugs for Irritable Bowel Syndrome, Dr. Hsin

3:40 PM: Stanford University- SPARK at Stanford, Charge-Altering Releasable Transporters (CARTS): New Materials enable a New Platform Technology for Gene Delivery, Vaccinations, and Cancer Immunotherapy, Tim Blake

4:00 PM: SPARK Taiwan, Novel NMDA Modulator: RS-D7, Jane Tseng

4:20 PM: Stanford University- SPARK at Stanford, Design of Muscle Stem Cell Targeting Prodrug for Muscle Regeneration, Adelaida Palla

4:40 PM: SPARK Germany, Recombinant human Neuregulin1 (rhNRG1) for the treatment of Schwann cell-‐derived nerve sheath tumors, Helen Morrison

Session ID: 543606